Comparison of Outcomes of Enoxaparin Bridge Therapy in HeartMate II versus HeartWare HVAD Recipients.

Mitulkumar Patel Tania Ahuja Serena ArnoukClaudia GideaAlex ReyentovichDeane E SmithNader MoazamiJohn PapadopoulosTyler C Lewis

Published in: Journal of cardiovascular pharmacology and therapeutics (2021)

We found the use of enoxaparin "bridge" therapy to be associated with a higher incidence of bleeding in patients with a HM II device compared with an HVAD device. Assessment of device- and patient-specific factors should be evaluated to minimize bleeding events.

Keyphrases

venous thromboembolism
atrial fibrillation
left ventricular assist device
risk factors
insulin resistance
cell therapy
skeletal muscle
replacement therapy